These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 22345594)

  • 1. Mechanistic view of risk factors for venous thromboembolism.
    Reitsma PH; Versteeg HH; Middeldorp S
    Arterioscler Thromb Vasc Biol; 2012 Mar; 32(3):563-8. PubMed ID: 22345594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathophysiology of venous thrombosis.
    López JA; Chen J
    Thromb Res; 2009; 123 Suppl 4():S30-4. PubMed ID: 19303501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral arterial disease and Virchow's triad.
    Bennett PC; Silverman SH; Gill PS; Lip GY
    Thromb Haemost; 2009 Jun; 101(6):1032-40. PubMed ID: 19492144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microparticles in vascular disorders: how tissue factor-exposing vesicles contribute to pathology and physiology.
    Kleinjan A; Böing AN; Sturk A; Nieuwland R
    Thromb Res; 2012 Oct; 130 Suppl 1():S71-3. PubMed ID: 23026670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of procoagulants and anticoagulants in the development of venous thromboembolism.
    Bertina RM
    Thromb Res; 2009; 123 Suppl 4():S41-5. PubMed ID: 19303503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of selectins and fibrinolysis in VTE.
    Wakefield TW; Myers DD; Henke PK
    Thromb Res; 2009; 123 Suppl 4():S35-40. PubMed ID: 19303502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular risk factors in idiopathic compared to risk-associated venous thromboembolism: A focus on fibrinogen, factor VIII, and high-sensitivity C-reactive protein (hs-CRP).
    Luxembourg B; Schmitt J; Humpich M; Glowatzki M; Dressler D; Seifried E; Lindhoff-Last E
    Thromb Haemost; 2009 Oct; 102(4):668-75. PubMed ID: 19806251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet microparticles and vascular cells interactions: a checkpoint between the haemostatic and thrombotic responses.
    Morel O; Morel N; Freyssinet JM; Toti F
    Platelets; 2008 Feb; 19(1):9-23. PubMed ID: 18231934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microparticles: an introduction.
    Boulanger CM; Dignat-George F
    Arterioscler Thromb Vasc Biol; 2011 Jan; 31(1):2-3. PubMed ID: 21160061
    [No Abstract]   [Full Text] [Related]  

  • 10. Venous thromboembolism and arterial complications.
    Prandoni P; Piovella C; Pesavento R
    Semin Respir Crit Care Med; 2012 Apr; 33(2):205-10. PubMed ID: 22648494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of inflammation in venous thromboembolism and the link between arterial and venous thrombosis.
    Poredos P; Jezovnik MK
    Int Angiol; 2007 Dec; 26(4):306-11. PubMed ID: 18091697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis of venous thromboembolism: when the cup runneth over.
    Lippi G; Franchini M
    Semin Thromb Hemost; 2008 Nov; 34(8):747-61. PubMed ID: 19214913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulation strategies for venous thromboembolism.
    Peterson D; Harward S; Lawson JH
    Perspect Vasc Surg Endovasc Ther; 2009 Jun; 21(2):125-32. PubMed ID: 19767406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased levels of microparticles originating from endothelial cells, platelets and erythrocytes in subjects with metabolic syndrome: relationship with oxidative stress.
    Helal O; Defoort C; Robert S; Marin C; Lesavre N; Lopez-Miranda J; Risérus U; Basu S; Lovegrove J; McMonagle J; Roche HM; Dignat-George F; Lairon D
    Nutr Metab Cardiovasc Dis; 2011 Sep; 21(9):665-71. PubMed ID: 20399083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-derived microparticles: a new challenge in neuroscience.
    Doeuvre L; Plawinski L; Toti F; Anglés-Cano E
    J Neurochem; 2009 Jul; 110(2):457-68. PubMed ID: 19457085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk assessment as a guide for the prevention of the many faces of venous thromboembolism.
    Caprini JA
    Am J Surg; 2010 Jan; 199(1 Suppl):S3-10. PubMed ID: 20103082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiology of venous thromboembolism.
    Nielsen HK
    Semin Thromb Hemost; 1991; 17 Suppl 3():250-3. PubMed ID: 1754882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for venous thromboembolism in children.
    Gerotziafas GT
    Int Angiol; 2004 Sep; 23(3):195-205. PubMed ID: 15765033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood viscosity and thrombosis: clinical considerations.
    Smith BD; La Celle PL
    Prog Hemost Thromb; 1982; 6():179-201. PubMed ID: 6762612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelets and Platelet-Derived Microvesicles as Immune Effectors in Type 2 Diabetes.
    Cortez-Espinosa N; Mayoral LP; Perez-Campos E; Cabrera Fuentes HA; Mayoral EP; Martínez-Cruz R; Canseco SP; Andrade GM; Cruz MM; Velasco IG; Cruz PH
    Curr Vasc Pharmacol; 2017; 15(3):207-217. PubMed ID: 28128064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.